{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:46Z","timestamp":1791178486042,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3506,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.exphem.2012.07.007","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T18:53:24Z","timestamp":1343242404000},"page":"906-913.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia"],"prefix":"10.1016","volume":"40","author":[{"given":"Anna","family":"Kreutzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taina","family":"Jaatinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmi","family":"Vakkila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"Ekblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Seggewiss-Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e9s","family":"Guerci-Bresler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Partanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.07.007_bib1","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.07.007_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2012.07.007_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/leu.2008.273","article-title":"Does chemotherapy modify the immune surveillance of hematological malignancies?","volume":"23","author":"Barrett","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.07.007_bib4","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.07.007_bib5","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.07.007_bib6","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.exphem.2012.07.007_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri1570","article-title":"MHC class I molecules and KIRs in human history, health and survival","volume":"5","author":"Parham","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2012.07.007_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.trim.2005.03.002","article-title":"KIR genes","volume":"14","author":"Middleton","year":"2005","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.exphem.2012.07.007_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clim.2009.04.009","article-title":"Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference","volume":"133","author":"Locatelli","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.exphem.2012.07.007_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.2008.00658.x","article-title":"Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells","volume":"224","author":"Joncker","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2012.07.007_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2249.2009.03983.x","article-title":"Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias","volume":"157","author":"Moretta","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2012.07.007_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.exphem.2012.07.007_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2012.07.007_bib14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.07.007_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.07.007_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2012.07.007_bib17","unstructured":"A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria;\u00a02010."},{"key":"10.1016\/j.exphem.2012.07.007_bib18","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/bcr3076","article-title":"Variants on the promoter region of PTEN affect breast cancer progression and patient survival","volume":"13","author":"Heikkinen","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.exphem.2012.07.007_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0039.2005.00473.x","article-title":"Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion","volume":"66","author":"Denis","year":"2005","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.exphem.2012.07.007_bib20","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.leu.2403525","article-title":"Identification of natural killer cell receptor phenotypes associated with leukemia","volume":"18","author":"Verheyden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.07.007_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2009.04.022","article-title":"Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease","volume":"34","author":"Zhang","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2012.07.007_bib22","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.2174\/092986711798184271","article-title":"Effects of BCR-ABL inhibitors on anti-tumor immunity","volume":"18","author":"Krusch","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.exphem.2012.07.007_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2012.07.007_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","article-title":"Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells","volume":"144","author":"Fei","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.07.007_bib25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2012.07.007_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells","volume":"111","author":"Molldrem","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2012.07.007_bib27","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2005-02-0479","article-title":"The antileukemia effect of\u00a0HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions","volume":"106","author":"Sconocchia","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.07.007_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","article-title":"Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in\u00a0vitro expanded natural killer cells, which are functionally enhanced by bortezomib","volume":"113","author":"Yong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.07.007_bib29","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1016\/j.molimm.2008.04.016","article-title":"KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients","volume":"45","author":"van der Meer","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.exphem.2012.07.007_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.07.007_bib31","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/01.tp.0000235859.24513.43","article-title":"Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in\u00a0vivo T-cell depleted unrelated stem cell transplantation","volume":"82","author":"Kroger","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2012.07.007_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0609.2009.01280.x","article-title":"Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation","volume":"83","author":"Giebel","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2012.07.007_bib33","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2010-03-273706","article-title":"Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma","volume":"116","author":"Gabriel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.07.007_bib34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1084\/jem.20042158","article-title":"Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci","volume":"201","author":"Carrington","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.exphem.2012.07.007_bib35","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1182\/blood-2009-08-236943","article-title":"Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Venstrom","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.07.007_bib36","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/eji.200939728","article-title":"Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity","volume":"39","author":"Ghio","year":"2009","journal-title":"Eur J Immunol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12003025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12003025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:05Z","timestamp":1759566605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12003025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0301472X12003025"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.07.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}